Obesity Market to Showcase Robust Growth at a CAGR of 23% by 2032 | DelveInsight

The obesity market is expected to grow significantly owing to an increase in upcoming novel treatment options, increasing market size due to increasing prevalence, and increasing global healthcare investment and funding.

LAS VEGAS, Sept. 14, 2022 /PRNewswire/ -- DelveInsight's Obesity Market Insights report includes a comprehensive understanding of current treatment practices, obesity emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Obesity Market Report

• As per DelveInsight analysis, the obesity market size in the 7MM was approximately USD 1,052 million in 2021.
• As per the estimates, the total obesity prevalence among adults in the 7MM was approximately 182 million in 2021. 
• Leading obesity companies such as Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu Hengrui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others are developing novel obesity drugs that can be available in the obesity market in the upcoming years.
• The obesity therapies in the pipeline include Semaglutide oral, Tirzepatide, Cotadutide, BI 456906, RZL-012, NNC0174-0833, Pemvidutide, Tesomet, Xla1, IBI362, HSG4112, S-237648, ARD-101, LY 3437943, Leucine/sildenafil, MBL949, TG103, SHR20004, CT-868, PF-06882961, NNC0165-1875, XW 003, LY3502970, EMP16-01, NNC-0480-0389, NNC0247 0829, and others.
• The dynamics of the obesity market are anticipated to change during the forecast period, owing to the expected launch of new therapies.

Discover which therapies are expected to grab major obesity market share @Obesity Market Report

Obesity Overview

Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned. The causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as behavior and culture, have a direct influence.

Obesity symptoms extend beyond increased body fat, and it can cause skin problems, shortness of breath, difficulty sleeping, and other symptoms. Some symptoms are even known to raise a person's likelihood of developing certain diseases and disorders. These can be life-threatening or even fatal in some situations.

Obesity Epidemiology Segmentation

As per DelveInsight estimates, there were approximately 182 million prevalent cases of obesity in adults in the 7MM in 2021.

Among the 7MM, the EU5 had recorded the highest obesity prevalence in 2021.

The obesity market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total prevalent cases of obesity 
• Total Obesity patients seeking help
• Total treated cases of obesity

Download the report to understand which factors are driving obesity epidemiology trends @Obesity Epidemiological Insights

Obesity Treatment Market 

Obesity treatments include losing weight through healthy eating, increasing physical activity, and making other lifestyle changes. Some people may benefit from weight-management programs to lose or maintain their weight, and some obese people cannot lose enough weight to improve their health or maintain weight loss.

Moreover, when a patient has not been able to lose weight through diet and exercise and meets one of the following criteria, the doctor may consider a weight-loss drug for the patient: body mass index (BMI) greater than 30 or BMI greater than 27 and the patient has a serious medical problem related to obesity, such as diabetes or high blood pressure. Prescription medications for treating obesity and overweight work in a variety of ways. Some medications, for example, may help you feel less hungry or full sooner, and other medications may make it more difficult for the body to absorb fat from food.

Furthermore, the FDA-approved obesity drugs currently available on the market for treatment include Contrave (Currax Pharmaceuticals), Saxenda (Novo Nordisk), Wegovy (Novo Nordisk), Qsymia, (Vivus/IEH Biopharma), Xenical (Hoffmann-La Roche/H2 Pharma), Imcivree (Rhythm Pharmaceuticals), and others. 

To know more about obesity treatment options, visit @New Treatment for Obesity 

Obesity Pipeline Therapies and Key Companies

• Semaglutide oral: Novo Nordisk
• Tirzepatide: Eli Lilly and Company
• Cotadutide: MedImmune
• BI 456906: Boehringer Ingelheim
• RZL-012: Raziel Therapeutics
• NNC0174-0833: Novo Nordisk
• Pemvidutide: Altimmune
• Tesomet: Saniona
• Xla1: YSOPIA Bioscience
• IBI362: Innovent Biologics
• HSG4112: Glaceum
• S-237648: Shionogi
• ARD-101: Aardvark Therapeutics
• LY 3437943: Eli Lilly and Company
• Leucine/sildenafil: NuSirt Biopharma
• MBL949: Novartis
• TG103: CSPC Baike (Shandong) Biopharmaceutical
• SHR20004: Jiangsu HengRui Medicine
• CT-868: Carmot Therapeutics
• PF-06882961: Pfizer
• NNC0165-1875: Novo Nordisk
• XW 003: Sciwind Biosciences
• LY3502970: Eli Lilly and Company
• EMP16-01: Empros Pharma
• NNC-0480-0389: Novo Nordisk
• NNC0247 0829: Novo Nordisk

Learn more about the FDA-approved obesity drugs @Drugs for Obesity Treatment 

Obesity Market Dynamics

Obesity management and its associated comorbidities have evolved. Obesity treatment currently aims to reduce body weight and fat percentage to prevent the onset of obesity-related health problems and improve the patient's overall health. More companies are focusing on the upcoming obesity therapeutic pipeline to address the challenges mentioned above.

Moreover, obesity cases in children and adults have increased due to sedentary lifestyles and other risk factors associated with obesity, accelerating obesity market growth. Furthermore, many government and non-government organizations are attempting to raise awareness of obesity among patients. As a result, patients will seek appropriate treatment, further expanding the obesity market.

However, certain factors are slowing down the obesity market growth. The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the obesity market growth.

Moreover, there is a significant disparity in the disease staging systems used in the obesity treatment landscape. As a result, there is a need to agree on when and if different staging systems should be used. Furthermore, obesity-related comorbidities necessitate additional medications and treatments, complicating obesity management and increasing costs and patient adherence.

Scope of the Obesity Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Obesity Companies: Hoffmann-La Roche, H2 Pharma, Vivus, IEH Biopharma, Orexigen Therapeutics, Currax, Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others
• Key Obesity Therapies: Semaglutide oral, Tirzepatide, Cotadutide, BI 456906, RZL-012, NNC0174-0833, Pemvidutide, Tesomet, Xla1, IBI362, HSG4112, S-237648, ARD-101, LY 3437943, Leucine/sildenafil, MBL949, TG103, SHR20004, CT-868, PF-06882961, NNC0165-1875, XW 003, LY3502970, EMP16-01, NNC-0480-0389, NNC0247 0829, and others
• Therapeutic Assessment: Obesity current marketed and emerging therapies
• Obesity Market Dynamics: Obesity market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Obesity Market Access and Reimbursement

Discover more about drugs for obesity in development @Obesity Clinical Trials

Table of Contents

Get in touch with our business executive @Healthcare Due Diligence Services 

Related Reports

Obesity Epidemiology Forecast

Obesity Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and obesity epidemiology trends.

Obesity Pipeline

Obesity Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key obesity companies, including Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, among others.

Hypothalamic Obesity Market

Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others.

Hypothalamic Obesity Pipeline

Hypothalamic Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others.

HET Obesity/POMC Deficiency Obesity Pipeline

HET Obesity/POMC Deficiency Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others.

HET Obesity/POMC Deficiency Obesity Market

HET Obesity/POMC Deficiency Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others.

Other Trending Reports

Diagnostic Imaging Equipment Market | Invasive Candidiasis Market | Sialidosis Market | Filgrastim Biosimilar Insight | Pain Management Devices Market | Primoridal Dwarfism Market | Non-cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Cystinuria Market | Deep Vein Thrombosis Market | Acquired Immunodeficiency Syndrome Market | Gene and Cell Therapies in Rare Disorder Market | Pediatric Growth Hormone Deficiency (PGHD) Market | Pain Management Devices Market | Diagnostic Imaging Equipment Market | Ischemic Stroke Market | Paget's Disease Market | Resorbable Vascular Scaffold Market | Rosai–Dorfman disease (RDD) Market | Salivary Gland Infection Market | Sandhoff Disease Market | Scedosporium Infection Market | Structural Heart Devices Market | Vascular Graft Devices Market | Vascular Stents Market | Vein Illumination Devices Market | Ventricular Assist Devices (VAD) Market | Adrenocortical Carcinoma Market | Cystinuria Market Market | Myopia Treatment Devices Market | Urology Ultrasounds Devices Market | Sly Syndrome Market | Human Papillomavirus-Positive Oropharyngeal | Cancer Market | Tuberculosis Market | Plasmodium Vivax Malaria Market | Oncolytic Virus Cancer Therapy Pipeline | Facial Lines Market | Rosacea Market | Polycystic Kidney Disease Market | Oropharyngeal Cancer Market | NPC Market | Immune Thrombocytopenia Market

Related Healthcare Blogs

Obesity: A Global Concern

Weight Loss and Obesity Market

Obesity Treatment Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg